Why it’s time for a change in the management of adolescent and adult medulloblastoma

References

• Smoll NR, Drummond KJ. The incidence of medulloblastomas and primitive neurectodermal tumours in adults and children. J Clin Neurosci. 2012;19:1541–1544.
   Google Scholar
• CBTRUS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2004-2007. Hinsdale (IL): Source: Central Brain Tumor Registry of the United States; 2011.
   Google Scholar
• Cho YJ, Tsherniak A, Tamayo P, et al. Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. J Clin Oncol. 2011 Apr 10;29(11):1424-1430.
   Google Scholar
• Thompson MC, Fuller C, Hogg TL, et al. Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol. 2006;24:1924–1931. Epub 2006/03/29.
   Google Scholar
• Northcott PA, Korshunov A, Witt H, et al. Medulloblastoma comprises four distinct molecular variants. J Clin Oncol. 2011 Apr 10;29(11):1408-1414.
   Google Scholar
• Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol. 2012;123:465–472.
   Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821–831.
   Google Scholar
• Lassaletta A, Ramaswamy V. Medulloblastoma in adults: they’re not just big kids. Neuro Oncol. 2016;18:895–897.
   Google Scholar
• Smoll NR. Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer. 2012 Mar 1;118(5):1313-1322.
   Google Scholar
• Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol. 2012;123:473–484.
   Google Scholar
• Keegan TH, Ries LA, Barr RD, et al. Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults. Cancer. 2016;122:1009–1016.
   Google Scholar
• Remke M, Hielscher T, Northcott PA, et al. Adult medulloblastoma comprises three major molecular variants. J Clin Oncol. 2011;29:2717–2723.
   Google Scholar
• Northcott PA, Hielscher T, Dubuc A, et al. Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. Acta Neuropathol. 2011;122:231–240. Epub 2011/06/18.
   Google Scholar
• Padovani L, Sunyach MP, Perol D, et al. Common strategy for adult and pediatric medulloblastoma: a multicenter series of 253 adults. Int J Radiat Oncol Biol Phys. 2007;68:433–440. Epub 2007/05/15.
   Google Scholar
• Selek U, Zorlu F, Hurmuz P, et al. Craniospinal radiotherapy in adult medulloblastoma. Strahlenther Onkol. 2007;183:236–240. Epub 2007/05/15.
   Google Scholar
• Kann BH, Lester-Coll NH, Park HS, et al. Adjuvant chemotherapy and overall survival in adult medulloblastoma. Neuro Oncol. 2016.
   Google Scholar
• Greenberg HS, Chamberlain MC, Glantz MJ, et al. Adult medulloblastoma: multiagent chemotherapy. Neuro-Oncology. 2001;3:29–34.
   Google Scholar
• Prados MD, Warnick RE, Wara WM, et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995;32:1145–1152. Epub 1995/07/15.
   Google Scholar
• King AA, Seidel K, Di C, et al. long-term neurologic health and psychosocial function of adult survivors of childhood medulloblastoma/pnet: a report from the childhood cancer survivor study. Neuro Oncol. 2016.
   Google Scholar
• Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol. 2014;32:886–896. Epub 2014/02/05.
   Google Scholar
• Ramaswamy V, Remke M, Adamski J, et al. Medulloblastoma subgroup-specific outcomes in irradiated children: who are the true high-risk patients? Neuro Oncol. 2016 Feb;18(2):291-297.
   Google Scholar
• Clifford SC, Lannering B, Schwalbe EC, et al. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: results from the multi-center HIT-SIOP-PNET4 clinical trial. Oncotarget. 2015 Nov 17;6(36):38827-38839.
   Google Scholar
• Kool M, Korshunov A, Pfister SM. Update on molecular and genetic alterations in adult medulloblastoma. Memo. 2012;5:228–232.
   Google Scholar
• Zhao F, Ohgaki H, Xu L, et al. Molecular subgroups of adult medulloblastoma: a long-term single-institution study. Neuro Oncol. 2016;18:982–990.
   Google Scholar
• Korshunov A, Remke M, Werft W, et al. Adult and pediatric medulloblastomas are genetically distinct and require different algorithms for molecular risk stratification. J Clin Oncol. 2010;28:3054–3060.
   Google Scholar
• Remke M, Ramaswamy V, Peacock J, et al. TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol. 2013;126:917–929. Epub 2013/11/01.
   Google Scholar
• Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell. 2014;25:393–405.
   Google Scholar
• Snuderl M, Triscott J, Northcott PA, et al. Deep sequencing identifies IDH1 R132S mutation in adult medulloblastoma. J Clin Oncol. 2015 Feb 20;33(6):e27-31.
   Google Scholar
• Brandes AA, Franceschi E, Tosoni A, et al. Long-term results of a prospective study on the treatment of medulloblastoma in adults. Cancer. 2007;110:2035–2041. Epub 2007/09/08.
   Google Scholar
• Carrie C, Lasset C, Blay JY, et al. Medulloblastoma in adults: survival and prognostic factors. Radiother Oncol. 1993;29:301–307. Epub 1993/12/01.
   Google Scholar
• Zhang N, Ouyang T, Kang H, et al. Adult medulloblastoma: clinical characters, prognostic factors, outcomes and patterns of relapse. J Neurooncol. 2015;124:255–264.
   Google Scholar
• Kunschner LJ, Kuttesch J, Hess K, et al. Survival and recurrence factors in adult medulloblastoma: the M.D. Anderson cancer center experience from 1978 to 1998. Neuro Oncol. 2001;3:167–173. Epub 2001/07/24.
   Google Scholar
• Frost PJ, Laperriere NJ, Wong CS, et al. Medulloblastoma in adults. Int J Radiat Oncol Biol Phys. 1995;32:951–957. Epub 1995/07/15.
   Google Scholar
• Chan AW, Tarbell NJ, Black PM, et al. Adult medulloblastoma: prognostic factors and patterns of relapse. Neurosurgery. 2000;47:623–631; discussion 31-2. Epub 2000/09/12.
   Google Scholar
• Hartsell WF, Montag AG, Lydon J, et al. Treatment of medulloblastoma in adults. Am J Clin Oncol. 1992;15:207–211.
   Google Scholar
• Perreault S, Ramaswamy V, Achrol AS, et al. MRI surrogates for molecular subgroups of medulloblastoma. AJNR Am J Neuroradiol. 2014.
   Google Scholar
• Carrie C, Lasset C, Alapetite C, et al. Multivariate analysis of prognostic factors in adult patients with medulloblastoma. Retrospective study of 156 patients. Cancer. 1994;74:2352–2360.
   Google Scholar
• Tabori U, Sung L, Hukin J, et al. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian pediatric brain tumor consortium study. Cancer. 2005;103:1874–1880. Epub 2005/03/17.
   Google Scholar
• Cassady JR, Tonnesen GL, Wolfe LC, et al. Augmentation of vincristine neurotoxicity by irradiation of peripheral nerves. Cancer Treat Rep. 1980;64:963–965.
   Google Scholar
• Cox MC, Kusters JM, Gidding CE, et al. Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: a prospective analysis. Radiat Oncol. 2015;10:241.
   Google Scholar
• Tarbell NJ, Friedman H, Polkinghorn WR, et al. High-risk medulloblastoma: a pediatric oncology group randomized trial of chemotherapy before or after radiation therapy (POG 9031). J Clin Oncol. 2013;31:2936–2941. Epub 2013/07/17.
   Google Scholar
• Packer RJ, Gajjar A, Vezina G, et al. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol. 2006;24:4202–4208.
   Google Scholar
• Taylor RE, Bailey CC, Robinson K, et al. Results of a randomized study of preradiation chemotherapy versus radiotherapy alone for nonmetastatic medulloblastoma: the international society of paediatric oncology/United Kingdom children’s cancer study group PNET-3 study. J Clin Oncol. 2003;21:1581–1591. Epub 2003/04/17.
   Google Scholar
• Gajjar A, Chintagumpala M, Ashley D, et al. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol. 2006;7:813–820. Epub 2006/10/03.
   Google Scholar
• Tabori U, Sung L, Hukin J, et al.; Canadian pediatric brain tumor C. Medulloblastoma in the second decade of life: a specific group with respect to toxicity and management: a Canadian pediatric brain tumor consortium study. Cancer. 2005;103:1874–1880.
   Google Scholar
• Brandes AA, Bartolotti M, Marucci G, et al. New perspectives in the treatment of adult medulloblastoma in the era of molecular oncology. Crit Rev Oncol Hematol. 2015;94:348–359.
   Google Scholar
• von Bueren AO, Friedrich C, von Hoff K, et al. Metastatic medulloblastoma in adults: outcome of patients treated according to the HIT2000 protocol. Eur J Cancer. 2015;51:2434–2443.
   Google Scholar
• Franceschi E, Bartolotti M, Paccapelo A, et al. Adjuvant chemotherapy in adult medulloblastoma: is it an option for average-risk patients? J Neurooncol. 2016;128:235–240.
   Google Scholar
• Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med. 2009;361:1173–1178.
   Google Scholar
• Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res. 2013;19:6305–6312. Epub 2013/10/01.
   Google Scholar
• Robinson GW, Orr BA, Wu G, et al. Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032. J Clin Oncol. 2015;33:2646–2654. Epub 2015/07/15.
   Google Scholar
• Shou Y, Robinson DM, Amakye DD, et al. A five-gene hedgehog signature developed as a patient preselection tool for hedgehog inhibitor therapy in medulloblastoma. Clin Cancer Res. 2015;21:585–593. Epub 2014/12/05.
   Google Scholar
• Lucas JT Jr., Wright KD. Vismodegib and physeal closure in a pediatric patient. Pediatr Blood Cancer. 2016;63:2058.
   Google Scholar
• Tabori U, Sung L, Hukin J, et al. Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. Int J Radiat Oncol Biol Phys. 2006;64:402–407. Epub 2005/10/04.
   Google Scholar
• Ramaswamy V, Remke M, Bouffet E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol. 2013;14:1200–1207. Epub 2013/10/22.
   Google Scholar
• Armstrong GT, Liu Q, Yasui Y, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the childhood cancer survivor study. JNCI J Natl Cancer Inst. 2009;101:946–958.
   Google Scholar
• Mulhern RK, Palmer SL, Merchant TE, et al. Neurocognitive consequences of risk-adapted therapy for childhood medulloblastoma. J Clin Oncol. 2005;23:5511–5519. Epub 2005/08/20.
   Google Scholar
• Mulhern RK, Palmer SL, Reddick WE, et al. Risks of young age for selected neurocognitive deficits in medulloblastoma are associated with white matter loss. J Clin Oncol. 2001;19:472–479. Epub 2001/02/24.
   Google Scholar
• Brinkman TM, Liptak CC, Delaney BL, et al. Suicide ideation in pediatric and adult survivors of childhood brain tumors. J Neurooncol. 2013;113:425–432.
   Google Scholar